Due to the extensive scientific‐industry collaborations the vaccine field is evolving at an unprecedented speed. Yet, to stop the pandemics equal access to the vaccine all over the world, limiting the costs of vaccines and logistics, close monitoring and reporting of adverse events are absolutely necessary. Development of a successful SARS‐CoV‐2 vaccine should not slow down the studies on the effective broader antiviral treatments. If not for SARS‐CoV‐2, we will need it for another coronavirus or an inevitably emerging virus X.